SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PRESENTATION OF POSITIVE CLINICAL DATA FROM PHASE 1 STUDY OF FS222 (CD137/PD-L1) AT THE 2024 ASCO

The board of directors (the "**Board**") of the Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announced that invoX Pharma Limited ("**invoX**"), a wholly-owned subsidiary of the Company, has presented updated findings from the ongoing phase 1 study of FS222 (CD137/PD-L1) in patients with advanced solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation. These data demonstrated encouraging anti-tumour activity in multiple tumour types with a manageable safety profile.

FS222 is a novel tetravalent bispecific antibody, using invoX's proprietary Fcab® platform technology, that drives PD-L1 dependent CD137 agonism. The data presented are from 100 subjects in the ongoing first-in-human (FIH) dose-escalation phase 1 clinical trial of FS222 (NCT04740424) in patients with advanced solid tumours. The study is designed to evaluate safety and identify the maximum tolerated dose, with secondary objectives related to anti-tumour activity, pharmacokinetics, and pharmacodynamics.

As a monotherapy dosed once every 4 weeks, FS222 increased T cell proliferation and intratumoural CD8+ T cell infiltration across a wide range of doses. The rate of treatment related adverse events (TRAEs) was generally dose dependent. Overall, TRAEs were consistent with the intended dual mechanism of action of CD137 agonism and PD-L1-blockade and were generally manageable and reversible. Grade ≥ 3 TRAEs occurred in 36/100 subjects, with the most common including increases in aspartate aminotransferase and alanine aminotransferase, thrombocytopenia, neutropenia, and febrile neutropenia.

In the study, FS222 demonstrated encouraging anti-tumour activity in multiple tumour types. Responses (as defined by RECIST1.1 criteria) were observed in cutaneous melanoma (n=9), ovarian cancer (n=2), non-small cell lung cancer (NSCLC) (n=2), and one each for mucosal melanoma, triple negative breast cancer (TNBC), mesothelioma and MSS colorectal cancer. The rate of disease control (defined as the rate of complete responses, partial responses and stable disease combined) was 45.0% for all patients in the study.

In 19 patients with metastatic/advanced cutaneous melanoma previously treated with a PD-1 antibody the overall response rate (defined as the rate of complete responses and partial responses combined) was 47.4% and the disease control rate was 68.4%.

Enrollment in this phase 1 study of FS222 is ongoing and the study is exploring additional FS222 dose optimization. These data not only demonstrate encouraging anti-tumour activity of FS222 in multiple tumour types, but also provide important validation for invoX's antibody platform. The Group will accelerate the clinical development of FS222 and continue to develop more drugs using the Group's proprietary antibody platform.

About invoX

invoX is a research-driven global biopharmaceutical company using next-generation technology platforms to discover and develop innovative medicines that can change the lives of people around the world. invoX aspires to improve people's lives by creating access to innovative medicines that address their unmet healthcare needs. Incorporated in March 2021, invoX has a core focus on oncology and respiratory therapeutics, with Research, Clinical Development and Business Development activities in the UK, EU, and US.

For further information, please visit: https://invoxpharma.com/

About the mAb²® bispecific antibody technology platform

invoX's mAb²® bispecific antibody technology platform, which uses an Fcab® binding domain, enables rapid discovery and optimisation of differentiated drug product candidates. It has been used to generate a clinical pipeline of tetravalent mAb²® bispecific antibodies with a natural human antibody format, providing advantages such as a straightforward manufacturing process, favourable safety profile and strong biological potency.

About FS222

FS222 is a novel tetravalent, bispecific antibody that targets PD-L1 and CD137 and is currently in development as a single agent for the treatment of patients with solid tumours. The unique tetravalent structure of FS222 has been designed to deliver anti-tumour activity by simultaneously targeting immunosuppression within tumours by blocking the PD-L1 pathway, whilst promoting T cell activation through CD137 agonism in areas of PD-L1 expression, such as tumours.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 5 June 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.